FINWIRES · TerminalLIVE
FINWIRES

ASX:RMD

7 stories mentioning ASX:RMD

Every FINWIRES story that references ASX:RMD, newest first.

Asia

ResMed Completes Acquisition of Noctrix Health

ResMed (ASX:RMD) completed its acquisition of Noctrix Health, a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders, according to a Tuesday statement by the company.The acquisition broadens the company's clinical sleep health portfolio into an adjacent area with significant unmet need, focusing on the treatment of restless legs syndrome, the third most prevalent sleep disorder.The deal includes Noctrix's US Food and Drug Administration de novo-cleared Nidra tonic motor activation therapy, a clinically validated treatment that reduces restless leg syndrome symptoms and improves sleep quality in patients unresponsive to drug therapies.The company said the acquisition supports its 2030 strategy to scale connected home sleep and health solutions.

ASX:RMD
Asia

ResMed Rises After Partnership With Oura to Expand Sleep Health Education, Care Pathways

ResMed (ASX:RMD) shares were up almost 2% in recent Wednesday trade after the company said late Tuesday it has partnered with smart ring maker Oura to expand access to sleep health education and pathways to care.The company said in a statement that insights from wearable devices, including the Oura Ring, can help people better understand their sleep patterns and encourage informed conversations with healthcare providers about potential sleep disorders, including obstructive sleep apnea.Oura members who experience a higher number of nighttime breathing disturbances can connect to ResMed resources, including educational materials, a sleep assessment, the option to connect with an independent healthcare provider virtually or in-person, and an informative guide to support discussions with their healthcare provider, the company said.The experience is available to users of Oura Ring Gen3 and Oura Ring 4 with an active Oura Membership in the US, it added.

ASX:RMD
Asia

Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX

CSL (ASX:CSL) led losses on the Australian bourse so far this year at AU$23.2 billion, while ResMed (ASX:RMD) and Cochlear (ASX:COH) followed with losses of AU$10.6 billion, the Australian Financial Review reported Monday, citing Global X ETFs.Negative performing companies on the S&P/ASX 200 index collectively wiped out over AU$217 billion, said Marc Jocum, senior product and investment strategist at Global X ETFs.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:COHASX:CSLASX:RMD
Asia

Update: ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue; Shares Hit Over Two-Year Low

(Updates to add stock movement in the headline and last paragraph)ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.The company's shares fell past 4% in recent Friday trade, earlier hitting their lowest level since February 2024.

ASX:RMD
Asia

ASX Preview: Australian Shares Set to Rise as Oil Prices Ease; ANZ Group Holdings Posts Higher Fiscal H1 Cash Earnings, Operating Income

Australian shares are poised to rise on Friday as oil prices eased from earlier four-year highs amid volatile trading driven by escalating US-Iran tensions and fears over potential disruptions to Middle East crude supplies.Overnight, the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average rose 1%, 0.9%, and 1.6%, respectively.In the macroeconomy, the Australian manufacturing sector returned to modest growth in April, though the improvement masked growing strain from Middle East-driven supply chain disruptions, surging fuel costs, and continued weakness in orders and production, according to a survey by S&P Global.Australia's home value index edged 0.3% higher in April, registering its slowest pace of growth since January 2025 amid declines in Sydney and Melbourne, according to figures from Cotality.Australia's producer price indexes report is due at 11:30 am Sydney time.In corporate news, ANZ Group Holdings (ASX:ANZ) reported Friday fiscal first-half cash earnings of AU$1.242 per share on operating income of AU$11.2 billion, compared with cash earnings of AU$1.17 on operating income of AU$11 billion a year earlier.ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share on revenue of $1.43 billion, compared with earnings of $2.37 on revenue of $1.29 billion a year earlier.Coles Group (ASX:COL) sales revenue for the fiscal third quarter was AU$10.7 billion, up from AU$10.38 billion a year earlier.Australia's benchmark index fell 0.2% or 21.2 points to close at 8,665.80 on Thursday.

ASX 200ASX:ANZASX:COLASX:RMD
Asia

ResMed CFO to Retire

ResMed (ASX:RMD) said that Chief Financial Officer Brett Sandercock plans to retire, effective May 4, according to a Friday statement by the company.Aaron Bloomer will succeed Sandercock, who will remain an adviser to the chief executive through 2027, the company said.Bloomer was CFO of Exact Sciences, which was recently acquired by New York Stock Exchange-listed Abbott.

ASX:RMD
Asia

ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue

ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.

ASX:RMD